MAR 1 3 7005

EODW DTO)-1449/A and B (m	odified	Chamerout De	APPLICATION NO.:	08/932,227	ATTY. DOCKET NO.: \$1509.70029US00
ļ	RMATION D			FILING DATE:	Sept. 17, 1997	CONFIRMATION NO.: 5092
_	EMENT BY			APPLICANT:	Eric T. Fossel	
Sheet	1	of	1	GROUP ART UNIT:	1711	EXAMINER: Jeffrey C. Mullis

U.S. PATENT DOCUMENTS

Examiner's	Cite	U.S. Patent Doc	ument	Name of Patentee or Applicant of Cited	Date of Publication or Issue
Initials #	No.	Number	Kind Code	Document	of Cited Document MM/DD/YYYY
X		4,732,892		Sarpotdar, et al.	03-22-1988
4		5,028,435		Katz, et al.	07-02-1991
		5,476,852		Cauwenbergh	12-19-1995
		5,505,958		Bello, et al.	04-09-1996
. •		5,538,740		Abad	07-23-1996
		5,576,351		Yoshimura, et al.	11-19-1996
X		6,117,872		Maxwell, et al.	09-12-2000

FOREIGN PATENT DOCUMENTS

Examiner's	Cite	Fore	ign Patent Docur	nent	Name of Patentee or Applicant of Cited	Date of Publication of	Translation
Initials #	No.	Office/ Country	Number	Kind Code	Document Document	Cited Document MM-DD-YYYY	(Y/N)
				7			
							·

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		International Search Report for International Application Serial No. PCT/US05/05726 dated September 9, 2005.	
Ø,		International Search Report for International Application Serial No. PCT/US05/13228 dated July 5, 2005	·
a		International Search Report for International Application Serial No. PCT/US05/13230 dated October 28, 2005	

EXAMINER: DATE CONSIDERED:		<u> </u>		
1 - 06	EXAMINER:		DATE CONSIDERED:	
			1 ~ 06	

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with heat communication to Applicant.

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

APR 1 4 2006		·
FOR PROBLEM A and B (modified PTO/SB/08)	APPLICATION NO.: 08/932,227	ATTY. DOCKET NO.: \$1509.70029US00
INFORMATION DISCLOSURE	FILING DATE: September 17,1997	CONFIRMATION NO.: 5092
STATEMENT BY APPLICANT	APPLICANT: Eric T. Fossel	
Sheet I of I	GROUP ART UNIT: 1711	EXAMINER: Jeffrey C. Mullis

U.S. PATENT DOCUMENTS

Examiner's	Cite	U.S. Patent Doci	ument	Name of Patentee or Applicant of Cited	Date of Publication or Issue
Initials #	No.	Number	Kind Code	Document	of Cited Document MM-DD-YYYY
		4,681,897		L. Brand	07-21-1987
4		5,595,753		H. Hechtman	01-21-1997
					·

FOREIGN PATENT DOCUMENTS

Examiner's	Cite	Fore	ign Patent Docur	nent	Name of Patentee or Applicant of Cited	Date of Publication of	Translation
Initials #	No.	Office/ Country	Number	Kind Code	Document	Cited Document MM-DD-YYYY	(Y/N)

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
X		Pauly et al, Liposomes containing amino acids and peptides and proteins for skin care, Chemical Abstracts (1998), Vol. 113, No. 65069	Abstract
0			
			_

EXAMINER:	DATE CONSIDERED:	
	5-66	
•		

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[[]NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

APR 1 0 2005 W		
\ \$	APPLICATION NO.: 08/932,227	ATTY. DOCKET NO.: \$1509.70029US00
INFORMATION DISCLOSURE	FILING DATE: September 17,1997	CONFIRMATION NO.: 5092
STATEMENT BY APPLICANT	APPLICANT: Eric T. Fossel	
Sheet 1 of 1	GROUP ART UNIT: 1711	EXAMINER: Jeffrey C. Mullis

		N PATENT LITERATURE DOCUMENTS	
Examiner's initials #	No (book, magazine, journal, serial, sym	TAL LETTERS), title of the article (when appropriate), title of the item posium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
5	Argiolas, A., et al., "Nitric Oxide i Vol. 11, pp. 1339-1344 (1994).	is a Central Mediator of Penile Erection," Neuropharmacology,	•
8	Bunker, C.D., "Alteration in scalp and 0.1% hexyl nicotinate in alope	blood flow after the epicutaneous application of 3% minoxidil	
W		oxidil Increase Skin Blood Flow? A Laser Doppler Flowmetry	·
4		lved in cutaneous vasodilation during body heating in humans?",	
R		tric oxide-mediated penile erection in rats," Am. J. Physiol., Vol	
D	I-Sheng, T., "Evaluation of Vasulo Formosan Med. Assoc., Vol. 89, N	ogenic Impotence Using Dynamic Penile Washout Test," J. No. 11, pp. 992-996 (1990).	
7	cavernous tissue and circumflex ve	nine/nitric oxide pathway in relaxation of isolated human penile eins," Acta Physiol Scand, Vol. 149, pp. 385-392 (1993).	
K	Klemp, P., "Subcutaneous Blood I pp. 725-726 (1989).	Flow in Early Male Patter Baldness," J. Invest Dermatol, Vol. 92,	
X	Laan, E., et al., "Assessment of fer Psychophysiology, Vol. 32, pp. 47	male sexual arousal: Response specificity and construct validity," 6-485 (1995).	
5	Mathias, B. J. et al., "Topical Caps 74, No. 1, pp. 39-44 (1995).	saicin for Chronic Neck Pain," Am. J. Phys. Med. Rehabil., Vol.	
X		ng-Term Oral Administration of L-Arginine on the Rat Erectile Association, Inc., Vol. 158, pp. 942-947 (1997).	
K	Owen, J.A., et al., "Topical Nitrog Urology, Vol. 141, pp. 546-548 (1	lycerin: A Potential Treatment for Impotence," The Journal of 989).	
6		tal arteries to endothelium dependent and independent vasocilators menon," European Journal of Clinical Investigation, Vol. 25, pp.	
Q	Sonntag, M., et al., "Role of nitric European Journal of physiology, p	oxide in local blood flow control in the anaesthetized dog," pp. 194-199 (1992).	
0	Tseng, L.F., et al., "Increase of nit	iric oxide production by L-arginine potentiates i.c.v. administered ion in the mouse," European Jouranal of Pharmacology, Vol.	
M		diates Penile Erection in Cats," The Journal of Urology, Vol. 151,	
7	Whitmore, S.E., et al, "Acute Effe	ect of Topical Minoxidil on Digital Blood Flow in Patients with urnal of Rheumatology, Vol. 11, No. 1, pp. 50-54 (1995).	
EXAMINER:		DATE CONSIDERED:	

EXAMINER: Initial if reference considered, whether ornot citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).